Considering the potency and selectivity of SU11652 according to biochemical and cell-based assays, further preclinical study with animal models and clinical studies with FLT3-ITD -positive AML patients appears to be well warranted. The gene discussed is FLT3; the disease is acute myeloid leukemia.